Ozempic Gastroparesis Settlement: Claim Valuation Factors Overview

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Pharmacovigilance

The legacy of general health and science information has long provided a foundation for public understanding of wellness and disease prevention. This heritage, rooted in broad educational outreach, has historically emphasized lifestyle factors and environmental influences on health outcomes. Over time, this informational framework has expanded to address specific therapeutic contexts, including the use of medications such as Ozempic for metabolic conditions. As public awareness of pharmaceutical benefits grew, so did attention to potential adverse effects, particularly those affecting gastrointestinal function. This shift from general health promotion to targeted pharmacovigilance represents a natural evolution in health communication.

Find Out If You Qualify for Compensation →

From Pharmacovigilance to Occupational Exposure and Patient Harm

The transition now moves toward a more focused concern: the occupational exposure risk associated with the manufacturing and handling of such medications. In mass production settings, workers may encounter active pharmaceutical ingredients during synthesis, formulation, or packaging processes. Understanding the implications of such exposure requires careful consideration of workplace safety protocols and potential health consequences. This pivot from general health education to occupational hazard assessment underscores the need for rigorous monitoring and protective measures in industrial environments where these compounds are handled. Equally important is the assessment of patient harm from therapeutic use, which forms the basis of settlement considerations.

Ozempic and Gastroparesis: Mechanistic Link and Clinical Evidence

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Its pharmacological action slows gastric emptying, a mechanism that can lead to gastrointestinal adverse effects. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Gastroparesis, a condition characterized by delayed gastric emptying without mechanical obstruction, presents with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy. The mechanistic pathway linking Ozempic to gastroparesis is rooted in its GLP-1 receptor agonism, which inhibits gastric motility and slows gastric emptying. This effect can become pathological in susceptible individuals, leading to impaired gastric emptying. FDA FAERS adverse-event reports most frequently associated with Ozempic include NAUSEA (8652 reports); VOMITING (5578 reports); DIARRHOEA (5274 reports); CONSTIPATION (3859 reports); and IMPAIRED GASTRIC EMPTYING (2693 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). The presence of "impaired gastric emptying" as a reported event underscores the clinical recognition of this adverse effect. Additional gastrointestinal adverse reactions with a frequency of <5% associated with Ozempic include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with gastroparesis presentation, complicating differential diagnosis.

Risk Anchors and Settlement Considerations

Risk anchors for settlement considerations include the adequacy of warnings regarding Ozempic and gastroparesis. The prescribing information for Ozempic lists gastrointestinal adverse reactions but does not explicitly warn of gastroparesis as a distinct adverse event. The label notes that gastrointestinal adverse reactions occurred more frequently with Ozempic than placebo and that the majority of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the term "gastroparesis" is not used in the label, and the condition is not listed as a specific warning or precaution. This gap may be relevant in evaluating whether patients were adequately informed of the risk of developing gastroparesis. Settlement-related considerations for affected patients involve several factors. First, the timeline between exposure and documented harm is critical. Gastroparesis may develop after initiation of Ozempic, with symptoms often emerging during dose escalation or after prolonged use. The FAERS data show 2693 reports of impaired gastric emptying (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC), indicating a temporal association. Second, the severity and duration of gastroparesis symptoms, including need for hospitalization, nutritional support, or discontinuation of Ozempic, influence claim valuation. Third, the presence of pre-existing gastrointestinal conditions or other risk factors may affect causation analysis. Claim valuation factors also include the strength of the mechanistic link between Ozempic and gastroparesis. The pharmacological action of GLP-1 agonists on gastric emptying provides a plausible biological mechanism. Clinical trial data show higher rates of gastrointestinal adverse reactions with Ozempic compared to placebo, and dose-dependent increases in these reactions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The FAERS data further support a signal for impaired gastric emptying. However, individual cases require careful assessment of alternative causes, such as diabetic gastroparesis, which is common in the patient population using Ozempic. In summary, the evidence indicates that Ozempic is associated with gastrointestinal adverse reactions, including impaired gastric emptying, through its mechanism of delaying gastric emptying. The prescribing information does not explicitly warn of gastroparesis, which may be relevant to adequacy-of-warnings claims. Settlement considerations should weigh the strength of the mechanistic link, the temporal relationship between exposure and harm, and the severity of the patient's condition. Each claim will depend on individual medical records, including diagnostic confirmation of gastroparesis and exclusion of other causes.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying. This mechanism can lead to gastrointestinal adverse effects, and in some individuals, it may cause gastroparesis, a condition of delayed gastric emptying without obstruction. Clinical trials show higher rates of gastrointestinal adverse reactions with Ozempic compared to placebo, and FDA FAERS data include reports of impaired gastric emptying (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC).

Does the Ozempic label warn about gastroparesis?

The prescribing information for Ozempic lists gastrointestinal adverse reactions but does not explicitly warn of gastroparesis as a distinct adverse event. The term 'gastroparesis' is not used in the label, and the condition is not listed as a specific warning or precaution (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This gap may be relevant to adequacy-of-warnings claims.

What factors influence the valuation of an Ozempic gastroparesis claim?

Key factors include the timeline between Ozempic exposure and onset of gastroparesis, severity and duration of symptoms (e.g., hospitalization, nutritional support), presence of pre-existing gastrointestinal conditions, strength of the mechanistic link, and the adequacy of warnings. Each claim is evaluated based on individual medical records and exclusion of alternative causes.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.